KR20230169207A - 소아 중증 근무력증 치료용 조성물 및 방법 - Google Patents

소아 중증 근무력증 치료용 조성물 및 방법 Download PDF

Info

Publication number
KR20230169207A
KR20230169207A KR1020237038171A KR20237038171A KR20230169207A KR 20230169207 A KR20230169207 A KR 20230169207A KR 1020237038171 A KR1020237038171 A KR 1020237038171A KR 20237038171 A KR20237038171 A KR 20237038171A KR 20230169207 A KR20230169207 A KR 20230169207A
Authority
KR
South Korea
Prior art keywords
weeks
myasthenia gravis
seq
antibody
pediatric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237038171A
Other languages
English (en)
Korean (ko)
Inventor
숀 블랙
신두 람찬드렌
야오웨이 쥬
Original Assignee
모멘타 파머슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모멘타 파머슈티컬스 인코포레이티드 filed Critical 모멘타 파머슈티컬스 인코포레이티드
Publication of KR20230169207A publication Critical patent/KR20230169207A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020237038171A 2021-04-12 2022-04-12 소아 중증 근무력증 치료용 조성물 및 방법 Pending KR20230169207A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163173919P 2021-04-12 2021-04-12
US63/173,919 2021-04-12
US202163219155P 2021-07-07 2021-07-07
US63/219,155 2021-07-07
US202263266880P 2022-01-18 2022-01-18
US63/266,880 2022-01-18
PCT/US2022/024354 WO2022221239A1 (en) 2021-04-12 2022-04-12 Compositions and methods for treating pediatric myasthenia gravis

Publications (1)

Publication Number Publication Date
KR20230169207A true KR20230169207A (ko) 2023-12-15

Family

ID=83640966

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237038171A Pending KR20230169207A (ko) 2021-04-12 2022-04-12 소아 중증 근무력증 치료용 조성물 및 방법

Country Status (13)

Country Link
US (1) US20240182598A1 (https=)
EP (1) EP4323002A4 (https=)
JP (1) JP2024517087A (https=)
KR (1) KR20230169207A (https=)
AU (1) AU2022256389A1 (https=)
BR (1) BR112023021046A2 (https=)
CA (1) CA3216642A1 (https=)
CL (1) CL2023003033A1 (https=)
IL (1) IL307445A (https=)
JO (1) JOP20230247A1 (https=)
MX (1) MX2023012032A (https=)
PH (1) PH12023552841A1 (https=)
WO (1) WO2022221239A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113518783A (zh) 2018-07-20 2021-10-19 动量制药公司 FcRn抗体组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3081144A1 (en) * 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
KR102904658B1 (ko) * 2017-12-13 2025-12-29 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
WO2019160979A1 (en) * 2018-02-13 2019-08-22 The Brigham And Women's Hospital, Inc. Therapeutic fcrn-based bispecific monoclonal antibodies
WO2020023310A1 (en) * 2018-07-20 2020-01-30 Williams Eva Compositions of fcrn antibodies and methods of use thereof

Also Published As

Publication number Publication date
JOP20230247A1 (ar) 2023-10-12
MX2023012032A (es) 2023-12-08
EP4323002A4 (en) 2025-04-16
WO2022221239A1 (en) 2022-10-20
JP2024517087A (ja) 2024-04-19
BR112023021046A2 (pt) 2023-12-19
AU2022256389A1 (en) 2023-11-30
IL307445A (en) 2023-12-01
CL2023003033A1 (es) 2024-03-08
PH12023552841A1 (en) 2024-05-20
AU2022256389A9 (en) 2023-12-07
CA3216642A1 (en) 2022-10-20
EP4323002A1 (en) 2024-02-21
US20240182598A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
US20240336691A1 (en) Anti-tl1a antibody compositions and methods of treatment in the lung
KR20230117575A (ko) Fcrn 항체 및 이의 사용 방법
JP7051150B2 (ja) 気分障害の治療及び診断のための抗－配列類似性１９を持つファミリー、メンバーａ５抗体の用途
MXPA06014299A (es) Anticuerpos contra interleucina-13 humana y uso de los mismos.
US20250243289A1 (en) Methods of treating inflammatory diseases with combination of tl1a inhibitors and il23 inhibitors
AU2020266593B2 (en) Methods for treating or preventing asthma by administering an IL-33 antagonist
KR20230130681A (ko) Il-4r 길항제 투여에 의한 땅콩 알레르기를 치료하는방법 및 땅콩 알레르기원 특이적 면역치료를 강화하는 방법
KR20260050360A (ko) 만성 갑상선 안질환의 치료 방법
KR20240049351A (ko) Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
CA3130300A1 (en) Dosage and administration of anti-c5 antibodies for treatment of generalized myasthenia gravis
US20220041694A1 (en) Sars-cov-2 antibodies for treatment and prevention of covid-19
US20240182598A1 (en) Compositions and methods for treating pediatric myasthenia gravis
JP7696900B2 (ja) Ｉｌ－３３アンタゴニストを投与することによりｃｏｐｄを治療するための方法
US20250011417A1 (en) Methods for the treatment of thyroid eye disease
US20250340660A1 (en) Anti-cd30l antibodies, formulations therefor, and uses thereof
EA052034B1 (ru) Композиции и способы лечения детской миастении гравис
CN117120092A (zh) 用于治疗儿科重症肌无力的组合物和方法
US20250066467A1 (en) Methods for the treatment of myasthenia gravis
JP2026501785A (ja) 自己免疫疾患の治療のための抗ｃｄ３８抗体
WO2025193746A1 (en) Dosing regimens of anti-cd38 antibodies for treatment of subjects with immune thrombocytopenia
EA052645B1 (ru) Композиция для лечения и предупреждения covid-19
EA051865B1 (ru) Антитела к fcrn и способы их применения

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231106

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250411

Comment text: Request for Examination of Application